Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
With a market cap of 20.36B, Incyte(INCY) trades at $101.92. The stock has a price-to-earnings ratio of 15.35.
On 2026-06-15, Incyte(INCY) stock moved within a range of $101.32 to $107.99. With shares now at $101.92, the stock is trading +0.6% above its intraday low and -5.6% below the session's peak.
Trading volume for Incyte(INCY) stock has reached 1.63M, versus its average volume of 2.21M.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $66.74.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $66.74.
INCY News
Incyte, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Salveen Richter from Goldman Sachs maintained a Hold rating on the...
Incyte, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Sell rating on the...
In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Incyte, with a price target of $103.00. Claim 55% Off TipRanks Unlock...
Analyst ratings
55%
of 29 ratingsMore INCY News
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Incyte. The associated price target remains the same with $124.00. Unloc...
William Blair analyst Matt Phipps has maintained their neutral stance on INCY stock, giving a Hold rating on June 9. Claim 55% Off TipRanks Unlock powerful inve...
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced Phase 2 results from Cohort 1 of the Progress study evaluating zilurgisertib, an investigational oral a...
Incyte (INCY) announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant c...
Incyte (INCY) announced positive results from the Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic C...
...
Incyte (INCY) announced an update on their ongoing clinical study. The POD1UM-204 study, officially titled “An Umbrella Study of INCMGA00012 Alone and in Combi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.